1
David W Robertson, David T Wong, Joseph H Krushinski Jr: 3-aryloxy-3-substituted propanamines. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, June 11, 1991: US05023269 (65 worldwide citation)

The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.


2
David W Robertson, David T Wong, Joseph H Krushinski Jr: 3-aryloxy-3-substituted propanamines. Eli Lilly and Company, Robert A Conrad, September 11, 1990: US04956388 (56 worldwide citation)

The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.


3
James E Audia, David J Hibschman, Joseph H Krushinski Jr, Thomas E Mabry, Jeffrey S Nissen, Kurt Rasmussen, Vincent P Rocco, John M Schaus, Dennis C Thompson, David T Wong: Compounds having effects on serotonin-related systems. Eli Lilly and Company, Joseph A Jones, David E Boone, May 6, 1997: US05627196 (47 worldwide citation)

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for t ...


4
David J Hibschman, Joseph H Krushinski Jr, Kurt Rasmussen, Vincent P Rocco, John M Schaus, Dennis C Thompson: Compounds having effects on serotonin-related systems. Eli Lilly and Company, Arleen Palmberg, David E Boone, April 21, 1998: US05741789 (46 worldwide citation)

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for t ...


5
Joseph H Krushinski Jr, Kurt Rasmussen, Vincent P Rocco, John M Schaus, Dennis C Thompson: Compounds having effects on serotonin-related systems. Eli Lilly and Company, Joseph A Jones, David E Boone, November 19, 1996: US05576321 (42 worldwide citation)

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for t ...


6
James E Audia, Joseph H Krushinski Jr, Kurt Rasmussen, Vincent P Rocco, John M Schaus, Dennis C Thompson, David T Wong: Compounds having effects on serotonin-related systems. Eli Lilly and Company, Joseph A Jones, David E Boone, March 25, 1997: US05614523 (39 worldwide citation)

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for t ...


7
James E Audia, David J Hibschman, Joseph H Krushinski Jr, Thomas E Mabry, Jeffrey S Nissen, Kurt Rasmussen, Vincent P Rocco, John M Schaus, Dennis C Thompson, David T Wong: Compounds having effects on serotonin-related systems. Eli Lilly Company, Arleen Palmberg, David E Boone, August 4, 1998: US05789402 (37 worldwide citation)

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for t ...


8
Sung Y Cho, Thomas A Crowell, Bruce D Gitter, Philip A Hipskind, J Jeffry Howbert, Joseph H Krushinski Jr, Karen L Lobb, Brian S Muehl, James A Nixon: Non-peptide tachykinin receptor antagonists. Eli Lilly and Company, Paul J Gaylo, David E Boone, September 23, 1997: US05670499 (16 worldwide citation)

This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical form ...


9
Sung Y Cho, Thomas A Crowell, Bruce D Gitter, Philip A Hipskind, J Jeffry Howbert, Joseph H Krushinski Jr, Karen L Lobb, Brian S Muehl, James A Nixon: Non-peptide tachykinin receptor antagonists. Eli Lilly and Company, Paul J Gaylo, David E Boone, November 4, 1997: US05684033 (15 worldwide citation)

This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical form ...


10
Sandra A Filla, Joseph H Krushinski Jr, John Mehnert Schaus: Substituted heteroaromatic 5-HT.sub.1F agonists. Eli Lilly and Company, Robert D Titus, David E Boone, February 23, 1999: US05874427 (8 worldwide citation)

This invention provides novel 5-HT.sub.1F agonists of the Formula ##STR1## in which X, Y, E, R, A, B, and n are as defined in the specification, which are useful for the treatment of migraine and associated disorders.